压力和社会失败对尼古丁成瘾从奖赏到戒断神经生物学强化机制的影响。

IF 3.3 3区 医学 Q2 NEUROSCIENCES
Kokila Shankar, Sélène Zahedi, Olivier George
{"title":"压力和社会失败对尼古丁成瘾从奖赏到戒断神经生物学强化机制的影响。","authors":"Kokila Shankar, Sélène Zahedi, Olivier George","doi":"10.1007/s00213-025-06852-5","DOIUrl":null,"url":null,"abstract":"<p><p>Nicotine and cigarette/tobacco use continue to be a prevalent public health issue worldwide. The transition to nicotine addiction occurs through an allostatic cycle involving the stages of binging/intoxication, withdrawal/negative affective states, and preoccupation/anticipation. This review focuses on the psychological, neurobiological, and molecular mechanisms contributing to the negative affective state during withdrawal from nicotine with an emphasis on stress and how social defeat stress can affect these mechanisms. Psychologically, negative affect during withdrawal is thought to contribute to the transition from positive reinforcement of drug-taking to negative reinforcement of nicotine use. Nicotine binding to nicotinic acetylcholine receptors elicits a variety of neuronal signaling throughout the brain, over time producing within- and between-systems neuroadaptations across brain regions that govern reward, anxiety, pain, and stress responses. Continued nicotine use additionally dysregulates myriad molecular signaling pathways that directly affect nicotine intake/aversion and withdrawal-like symptoms. Throughout all of these mechanisms, non-pharmacological stress also plays an important role in mediating much of the negative affect associated with addiction. Social defeat stress increases a variety of neuropeptide signaling that consequently exacerbates drug taking and negative affective states. Understanding the mechanisms through which these stages manifest can better our understanding of addiction disease biology and provide novel avenues for therapeutic targets.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The influence of stress and social defeat on neurobiological reinforcement mechanisms across reward to withdrawal in nicotine addiction.\",\"authors\":\"Kokila Shankar, Sélène Zahedi, Olivier George\",\"doi\":\"10.1007/s00213-025-06852-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nicotine and cigarette/tobacco use continue to be a prevalent public health issue worldwide. The transition to nicotine addiction occurs through an allostatic cycle involving the stages of binging/intoxication, withdrawal/negative affective states, and preoccupation/anticipation. This review focuses on the psychological, neurobiological, and molecular mechanisms contributing to the negative affective state during withdrawal from nicotine with an emphasis on stress and how social defeat stress can affect these mechanisms. Psychologically, negative affect during withdrawal is thought to contribute to the transition from positive reinforcement of drug-taking to negative reinforcement of nicotine use. Nicotine binding to nicotinic acetylcholine receptors elicits a variety of neuronal signaling throughout the brain, over time producing within- and between-systems neuroadaptations across brain regions that govern reward, anxiety, pain, and stress responses. Continued nicotine use additionally dysregulates myriad molecular signaling pathways that directly affect nicotine intake/aversion and withdrawal-like symptoms. Throughout all of these mechanisms, non-pharmacological stress also plays an important role in mediating much of the negative affect associated with addiction. Social defeat stress increases a variety of neuropeptide signaling that consequently exacerbates drug taking and negative affective states. Understanding the mechanisms through which these stages manifest can better our understanding of addiction disease biology and provide novel avenues for therapeutic targets.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06852-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06852-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

尼古丁和香烟/烟草使用仍然是世界范围内普遍存在的公共卫生问题。向尼古丁成瘾的过渡是通过一个适应循环发生的,包括暴饮暴食/中毒、戒断/消极情感状态和专注/预期阶段。本文综述了尼古丁戒断过程中产生消极情感状态的心理、神经生物学和分子机制,重点介绍了压力以及社会失败压力如何影响这些机制。从心理上讲,戒断期间的负面影响被认为有助于从吸毒的积极强化到尼古丁使用的消极强化的转变。尼古丁与尼古丁乙酰胆碱受体结合,在整个大脑中引发各种神经元信号,随着时间的推移,在控制奖励、焦虑、疼痛和压力反应的大脑区域产生系统内和系统间的神经适应。持续使用尼古丁还会失调无数的分子信号通路,直接影响尼古丁摄入/厌恶和戒断样症状。在所有这些机制中,非药物应激在介导与成瘾相关的许多负面影响方面也起着重要作用。社会失败压力增加了各种神经肽信号,从而加剧了吸毒和消极的情感状态。了解这些阶段表现的机制可以更好地理解成瘾疾病生物学,并为治疗靶点提供新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The influence of stress and social defeat on neurobiological reinforcement mechanisms across reward to withdrawal in nicotine addiction.

Nicotine and cigarette/tobacco use continue to be a prevalent public health issue worldwide. The transition to nicotine addiction occurs through an allostatic cycle involving the stages of binging/intoxication, withdrawal/negative affective states, and preoccupation/anticipation. This review focuses on the psychological, neurobiological, and molecular mechanisms contributing to the negative affective state during withdrawal from nicotine with an emphasis on stress and how social defeat stress can affect these mechanisms. Psychologically, negative affect during withdrawal is thought to contribute to the transition from positive reinforcement of drug-taking to negative reinforcement of nicotine use. Nicotine binding to nicotinic acetylcholine receptors elicits a variety of neuronal signaling throughout the brain, over time producing within- and between-systems neuroadaptations across brain regions that govern reward, anxiety, pain, and stress responses. Continued nicotine use additionally dysregulates myriad molecular signaling pathways that directly affect nicotine intake/aversion and withdrawal-like symptoms. Throughout all of these mechanisms, non-pharmacological stress also plays an important role in mediating much of the negative affect associated with addiction. Social defeat stress increases a variety of neuropeptide signaling that consequently exacerbates drug taking and negative affective states. Understanding the mechanisms through which these stages manifest can better our understanding of addiction disease biology and provide novel avenues for therapeutic targets.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psychopharmacology
Psychopharmacology 医学-精神病学
CiteScore
7.10
自引率
5.90%
发文量
257
审稿时长
2-4 weeks
期刊介绍: Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信